StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) shareholders

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
53.5%
36M of 68M shares
Institutional holders
60
7 new, 7 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $145.62K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Weston Nichols
Joint filing with Lynx1 Capital Management LP (13.10%)
20,519,14813.10%13G (passive) amendmentJun 30, 2026
Lynx1 Capital Management LP
Joint filing with Weston Nichols (15.00%)
7,857,34715.00%13G (passive) amendmentJun 30, 2025
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more
6,417,8319.99%13G (passive) amendmentJun 30, 2026
Lampert Mark N
Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more
5,263,5419.99%13G (passive) amendmentMar 31, 2025
Parag Shah
Joint filing with K2 HealthVentures Equity Trust LLC (6.90%), Anup Arora (6.90%)
3,602,7006.90%13G (passive) amendmentDec 31, 2024
Phillip Gross
Joint filing with Adage Capital Management, L.P. (7.13%), Robert Atchinson (7.13%)
3,500,0007.13%13G (passive) amendmentDec 31, 2024
Readout Capital, LP
Joint filing with Readout Capital GP, LLC (5.40%), Matthew Smith (5.40%)
3,453,3885.40%13G (passive)Sep 21, 2026
Felix J. Baker
Joint filing with Baker Bros. Advisors LP (6.10%), Baker Bros. Advisors (GP) LLC (6.10%) and 1 more
2,828,9386.10%13D (active) amendmentApr 19, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of TCRXValueChange% of portfolio
Lynx1 Capital Management LP8,019,14811.83%$7.86M–0.91%
Bvf Inc/Il5,564,2908.21%$5.45M–0.14%
Baker Bros. Advisors LP2,784,7924.11%$2.73M–0.01%
Vanguard Capital Management LLC2,158,8313.19%$2.12M+4,5750.00%
Two Sigma Investments, LP1,949,6042.88%$1.91M+740,5950.00%
Renaissance Technologies LLC1,326,7991.96%$1.30M−37,9840.00%
Acadian Asset Management LLC1,305,8401.93%$1.28M+1,103,8530.00%
Deer Management Co. LLC1,245,5041.84%$1.22M–0.15%
Millennium Management LLC1,163,6111.72%$1.14M−296,6740.00%
Jacobs Levy Equity Management, Inc1,049,8061.55%$1.03M+241,4500.00%
Citadel Advisors LLC1,009,1071.49%$989.03K+690,6960.00%
BlackRock, Inc.994,6541.47%$974.86K−846,2980.00%
Kalehua Capital Management LLC909,7521.34%$891.65KNew0.28%
Boothbay Fund Management, LLC772,2411.14%$756.87KNew0.01%
Marshall Wace, Llp687,3641.01%$673.62K+450,0180.00%
DC Funds, LP630,0000.93%$617.46K–49.27%
Geode Capital Management, LLC584,8110.86%$573.40K−32,1410.00%
D. E. Shaw & Co., Inc.548,4020.81%$537.49K+228,8150.00%
Gsa Capital Partners Llp548,0870.81%$537.00K+169,1270.03%
Vanguard Fiduciary Trust Co363,9540.54%$356.68K+58,1820.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20266036M53.5%7 / 2312 / 76M2M
Q1 20266033M48.0%11 / 1521 / 116M2M
Q4 20256131M45.3%10 / 1819 / 203M7M
Q3 20257335M51.7%5 / 1930 / 121M2M
Q2 20258136M52.8%21 / 2618 / 327M11M
Q1 20259240M59.2%17 / 3319 / 134M5M
Q4 20248942M61.3%16 / 3115 / 163M4M
Q3 20248942M61.8%20 / 2518 / 117M2M
Q2 20248141M61.2%32 / 1815 / 169M2M
Q1 20246635M51.4%17 / 238 / 53M0M
Q4 20235432M47.5%22 / 134 / 04M0M
Q3 20233229M42.2%6 / 101 / 11M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

20 funds held TCRX in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of TCRXValue% of fundAs of
Vanguard Total Stock Market Index Fund1,500,3372.21%$1.47M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund575,5700.85%$564.12K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund293,6420.43%$317.13K0.00%May 31, 2026
iShares Micro-Cap ETF167,5330.25%$164.20K0.01%Jun 30, 2026
Fidelity Total Market Index Fund87,5660.13%$94.57K0.00%May 31, 2026
Fidelity Series Total Market Index Fund72,9140.11%$78.75K0.00%May 31, 2026
Ultra-Small Company Market Fund70,4000.10%$69.00K0.05%Jun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund69,4870.10%$75.05K0.01%May 31, 2026
Small Cap Equity Fund65,8130.10%$64.50K0.01%Jun 30, 2026
NVIT Multi-Manager Small Company Fund44,5000.07%$43.61K0.01%Jun 30, 2026
NVIT Small Cap Value Fund39,0000.06%$38.22K0.02%Jun 30, 2026
Strategic Advisers U.S. Total Stock Fund29,6120.04%$31.98K0.00%May 31, 2026
Vanguard Institutional Total Stock Market Index Fund29,6050.04%$29.02K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund28,7670.04%$31.07K0.00%May 31, 2026
Vanguard Balanced Index Fund19,3200.03%$18.94K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Gavin MacBeathChief Executive Officer, Director1,049,7671.55%Oct 2, 2026
Zoran ZdraveskiSee Remarks304,7160.45%Oct 2, 2026
Jason AmelloChief Financial Officer––Jan 22, 2026
Chrystal LouisChief Medical Officer––Jan 22, 2026
Leiden DworakSee Remarks5,6920.01%Jan 22, 2026
Bros. Advisors (GP) LLC BakerDirector––May 22, 2026
Keith WoodsDirector––May 22, 2026
667, L.P.Director256,2090.38%May 22, 2026
Katina DortonDirector––May 22, 2026
Garry A. NicholsonDirector––May 22, 2026
Gabriela GruiaDirector––May 22, 2026
Barbara KlenckeDirector70,0000.10%May 22, 2026
Bros. Advisors Lp BakerDirector––May 22, 2026
Julian BakerDirector––May 22, 2026
Felix BakerDirector––May 22, 2026
Brothers Life Sciences LP BakerDirector––May 22, 2026
Weston Nichols10% owner5,357,3477.90%Dec 23, 2025
Capital Management LP Lynx110% owner8,019,14811.83%Dec 23, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Gavin MacBeath
Chief Executive Officer, Director
Oct 1, 2026Award+1,000,000––1,049,767
Zoran Zdraveski
See Remarks
Oct 1, 2026Award+300,000––304,716
Capital Management LP Lynx1
10% owner
Dec 23, 2025Buy+6,232$0.90$5.61K8,019,148
Capital Management LP Lynx1
10% owner
Dec 22, 2025Buy+75,500$0.90$67.95K8,012,916
Capital Management LP Lynx1
10% owner
Dec 19, 2025Buy+80,069$0.90$72.06K7,937,416
Capital Management LP Lynx1
10% owner
May 20, 2025Buy+1,200,000$1.20$1.44M7,946,141
Capital Management LP Lynx1
10% owner
May 19, 2025Buy+1,388,794$1.20$1.67M6,746,141
Weston Nichols
10% owner
Dec 13, 2024Buy+100,000$2.90$290.00K5,357,347
Weston Nichols
10% owner
Dec 12, 2024Buy+31,800$3.01$95.72K5,257,347
Weston Nichols
10% owner
Nov 15, 2024Buy+947$4.34$4.11K5,225,547
Barbara Klencke
Director
Sep 23, 2024Buy+5,000$5.29$26.45K45,000
Barbara Klencke
Director
Aug 26, 2024Buy+5,000$5.53$27.65K40,000
Zoran Zdraveski
See Remarks
Aug 23, 2024Option exercise+54,895$4.85$266.24K67,111
Zoran Zdraveski
See Remarks
Aug 23, 2024Option exercise+25,000$3.27$81.75K92,111
Zoran Zdraveski
See Remarks
Aug 23, 2024Option exercise+13,125$1.81$23.76K105,236
Zoran Zdraveski
See Remarks
Aug 23, 2024Option exercise+64,166$2.49$159.77K169,402
Zoran Zdraveski
See Remarks
Aug 23, 2024Sale−164,686$5.78$951.89K4,716
Barbara Klencke
Director
Aug 23, 2024Buy+5,000$5.69$28.45K35,000
Timothy J. Barberich
Director
Dec 19, 2023Buy+317$4.97$1.58K67,027
Timothy J. Barberich
Director
Dec 18, 2023Buy+28,830$4.89$140.98K66,710
Barbara Klencke
Director
Dec 14, 2023Buy+5,000$5.08$25.40K30,000
Timothy J. Barberich
Director
Jun 2, 2023Buy+37,880$2.63$99.62K37,880
Capital Management LP Lynx1
10% owner
May 31, 2023Sale−15,000$2.52$37.80K5,225,000
Capital Management LP Lynx1
10% owner
May 31, 2023Sale−10,000$2.51$25.10K5,240,000
Capital Management LP Lynx1
10% owner
May 31, 2023Sale−400$2.51$1.00K5,224,600
Brian M. Silver
Chief Financial Officer
Dec 28, 2022Buy+3,158$1.56$4.93K32,885
Brian M. Silver
Chief Financial Officer
Dec 27, 2022Buy+2,842$1.50$4.26K29,727
David P. Southwell
Chief Executive Officer, Director
May 18, 2022Buy+10,000$3.55$35.50K171,569
David P. Southwell
Chief Executive Officer, Director
May 18, 2022Buy+15,000$3.62$54.30K161,569
667, L.P.
Director, 10% owner
May 11, 2022Buy+2,882$1.99$5.74K256,209
667, L.P.
Director, 10% owner
May 11, 2022Buy+22,983$1.99$45.74K2,528,583
667, L.P.
Director, 10% owner
May 10, 2022Buy+101,831$1.93$196.53K1,747,506
667, L.P.
Director, 10% owner
May 10, 2022Buy+40,800$1.70$69.36K145,498
667, L.P.
Director, 10% owner
May 10, 2022Buy+758,094$1.95$1.48M2,505,600
667, L.P.
Director, 10% owner
May 10, 2022Buy+95,060$1.95$185.37K253,327
667, L.P.
Director, 10% owner
May 10, 2022Buy+12,769$1.93$24.64K158,267
667, L.P.
Director, 10% owner
May 10, 2022Buy+325,373$1.70$553.13K1,645,675
Brian M. Silver
Chief Financial Officer
Mar 24, 2022Buy+15,000$3.40$51.00K26,885
David P. Southwell
Chief Executive Officer, Director
Dec 23, 2021Option exercise+48,670$1.97$95.88K146,569
Zoran Zdraveski
Chief Legal Officer
Sep 23, 2021Buy+4,716$7.48$35.28K4,716
Gavin MacBeath
Chief Scientific Officer
Sep 21, 2021Buy+57$6.19$35349,767
Brian M. Silver
Chief Financial Officer
Sep 21, 2021Buy+5,000$6.32$31.60K11,885
Gavin MacBeath
Chief Scientific Officer
Sep 20, 2021Buy+4,943$6.22$30.75K49,710
Brian M. Silver
Chief Financial Officer
Sep 9, 2021Buy+5,885$8.48$49.90K6,885
David P. Southwell
Chief Executive Officer, Director
Sep 8, 2021Buy+11,000$8.73$96.03K97,899
William Desmarais
Chief Business Officer
Aug 27, 2021Buy+2,500$9.08$22.70K2,500
667, L.P.
Director
Jul 20, 2021Buy+1,320,302$15.00$19.80M1,320,302
667, L.P.
Director
Jul 20, 2021Buy+104,698$15.00$1.57M104,698
Timothy J. Barberich
Director
Jul 20, 2021Conversion+33,259––33,259
Brian M. Silver
Chief Financial Officer
Jul 20, 2021Buy+1,000$15.00$15.00K1,000
Christoph H. Westphal
10% owner
Jul 20, 2021Buy+133,333$15.00$2.00M1,278,838
Christoph H. Westphal
10% owner
Jul 20, 2021Conversion+1,145,505––1,145,505

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.43%
2M shares short
Days to cover
4.7
At 0M shares a day
Change since last report
-11.3%
From 2M shares
Short volume, 20 days
47.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TScan Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 38,486 shares on Oct 13, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Zoran Zdraveski
Officer
Aug 23, 2024164,686$905.77KAug 23, 2024STOCK OPTION EXERCISE
Southwell David P
Director
May 15, 202385,911$346.22KMay 15, 2023Open Market

See a number that looks wrong?